Ken Bradley is a pharmaceutical executive and scientist with a passion for bringing novel therapeutics and cures to patients with viral and bacterial diseases. He is currently Global Head of Infectious Disease Discovery at Roche Pharma Research and Early Development (pRED) in Basel, Switzerland.
In addition, Ken serves as board member and co-chair of the Scientific Working Group for the INTREPID alliance, as a member of the strategic advisory board for Pathways to Antimicrobial Clinical Efficacy (PACE), the external advisory board for the Swiss National Centre of Competence in Research, AntiResist, and is a member of the Research & Science Working Group of the AMR Industry Alliance. Prior to joining Roche in 2015, Ken was Professor of Microbiology, Immunology and Molecular Genetics at the University of California, Los Angeles and director of the Molecular Screening Shared Resource (MSSR) at the California NanoSystems Institute.